Project Grant R01DK141807
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $465,155 to Brigham & Women's Hospital Inc. to conduct research on the role of the SRCAP gene in therapy-related clonal hematopoiesis and the development of therapy-related myeloid neoplasms. The award supports the development of a novel conditional mouse model to study the impact...
- This federal Project Grant award of $133,328 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to dissect the roles of the PPM1D and TP53 genes in hematopoietic stem cells and clonal hematopoiesis. The research aims to understand how mutations in these genes...
- This Project Grant award, valued at $801,000.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports research at The Children's Hospital Corporation, doing business as Boston Children's Hospital, to investigate the role of stress granules in red blood cell development, particularly during stress conditions. The research aims to uncover the...
- This $147,486.00 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of high-fat diet in hematopoiesis (blood cell formation) and clonal hematopoiesis, a condition associated with increased risk of myeloid diseases like myelodysplastic syndrome and acute myeloid leukemia. The award was made to the Regents of the University of Michigan, Ann Arbor for a project period running from Jul 9,...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $146,922.00 to the Albert Einstein College of Medicine to investigate genotype-environment interactions that drive dysfunction in hematopoietic stem and progenitor cells (HSPCs). The research aims to decipher how HSPC dysregulation, a major driver of myeloid malignancies like myelodysplastic syndromes (MDS), is influenced by the interplay between genetic...
- This $445,000 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The Children's Hospital of Philadelphia (CHOP) to investigate how the tropomyosin 1 gene product impacts the development of hematopoietic stem and progenitor cells and their precursors. The goal is to define genetic determinants of hematopoiesis that could enhance in vitro production of blood cells to support research and development of blood...
- This federal Project Grant award of $150,000.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The grant supports research by Mayo Clinic to study the clinical significance of somatic mosaic states in the context of short telomeres, which are associated with Telomere Biology Disorders (TBD). Specifically, the research aims to create and characterize a new...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $143,968.00 to support research on early detection and treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The research aims to examine whether markers of endothelial injury and complement overactivation can predict HSCT-TMA, as well...
- This federal Project Grant award of $242,048 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund research at Versiti Wisconsin, Inc. to investigate DNA damage responses and potential chromosomal abnormalities in hematopoietic stem and progenitor cells following genome editing. The goal is to enhance the understanding of genotoxicities and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $216,460 to Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations in hematopoiesis. The project aims to characterize blood system changes during embryogenesis and adult stages in zebrafish models, as well as leverage human induced pluripotent stem cells, to understand how co-occurring DDX41 and CUX1 mutations cooperate to...
This Project Grant award of $390,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on a novel mutation in the TASPASE1 gene and its impact on hematopoiesis and transcriptional regulation. The principal investigator at the University of Colorado-Denver is investigating how the TASPASE1V343M mutation disrupts proteolytic cleavage of the transcription factor TFIIA, leading to altered RNA polymerase II promoter occupancy and potentially contributing to an inherited bone marrow failure syndrome. The project aims to clarify the genetic etiology and molecular mechanisms underlying this novel marrow failure disorder, with the goal of informing the development of new targeted therapies. The award period runs from September 15, 2025 to June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $390.0k | 9/2/25 |